Literature DB >> 6138119

Response of pulmonary circulation to oral pirbuterol in chronic airflow obstruction.

A Peacock, C Busst, K Dawkins, D M Denison.   

Abstract

The effects of the oral beta agonist pirbuterol on pulmonary haemodynamics and gas exchange were studied in nine patients with severe irreversible airflow obstruction and moderate arterial hypoxaemia. After administration of 15 mg pirbuterol pulmonary vascular resistance fell by 19% but cardiac output rose by 24%, so that pulmonary arterial pressure showed no significant change. Systemic arterial oxygen pressure fell by 7%, limiting the rise in oxygen delivery to 21%. All changes were significant at the 2% level. These results show that pirbuterol dilates the pulmonary bed at the cost of a slight worsening of gas exchange, which is compensated by an independent rise in blood flow.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138119      PMCID: PMC1549403          DOI: 10.1136/bmj.287.6400.1178

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  9 in total

1.  Further observations on the course and prognosis of chronic obstructive lung disease.

Authors:  C F Diener; B Burrows
Journal:  Am Rev Respir Dis       Date:  1975-06

2.  Single-dose and dose-response studies with oral pirbuterol, a new beta agonist in chronic heart failure.

Authors:  R Canepa-Anson; J R Dawson; P Kuan; C A Warnes; P A Poole-Wilson; S R Reuben; G C Sutton
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

3.  Acute and chronic effects of pirbuterol on left ventricular ejection fraction and clinical status in severe congestive heart failure.

Authors:  W S Colucci; R W Alexander; G H Mudge; R E Rude; B L Holman; J Wynne; W Grossman; E Braunwald
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

4.  Hemodynamic effects of pirbuterol in conscious dogs.

Authors:  F L Gold; L D Horwitz
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

5.  Comparison of hemodynamic actions of pirbuterol and dobutamine on cardiac function in severe congestive heart failure.

Authors:  N A Awan; K E Needham; M K Evenson; D T Mason
Journal:  Am J Cardiol       Date:  1981-03       Impact factor: 2.778

6.  Tissue oxygen delivery and cor pulmonale in chronic obstructive pulmonary disease.

Authors:  E H Bergofsky
Journal:  N Engl J Med       Date:  1983-05-05       Impact factor: 91.245

7.  Controlled oxygen therapy and pulmonary heart failure.

Authors:  A C Ude; P Howard
Journal:  Thorax       Date:  1971-09       Impact factor: 9.139

8.  Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease.

Authors:  E Weitzenblum; C Hirth; A Ducolone; R Mirhom; J Rasaholinjanahary; M Ehrhart
Journal:  Thorax       Date:  1981-10       Impact factor: 9.139

9.  Clinical and haemodynamic effects of diazoxide in primary pulmonary hypertension.

Authors:  M Honey; L Cotter; N Davies; D Denison
Journal:  Thorax       Date:  1980-04       Impact factor: 9.139

  9 in total
  8 in total

Review 1.  Pulmonary hypertension due to chronic hypoxia.

Authors:  A Peacock
Journal:  BMJ       Date:  1990-03-24

2.  Treatment of pulmonary hypertension in chronic bronchitis and emphysema.

Authors:  J Rees
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-24

Review 3.  Can pulmonary vasodilators improve survival in cor pulmonale due to hypoxic chronic bronchitis and emphysema?

Authors:  K F Whyte; D C Flenley
Journal:  Thorax       Date:  1988-01       Impact factor: 9.139

Review 4.  Respiratory and allergic disease. II. Chronic obstructive airways disease and respiratory infections.

Authors:  K F Chung; P J Barnes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09

5.  Vasodilators in pulmonary hypertension.

Authors:  A Peacock
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

6.  Pulmonary vascular resistance in children with congenital heart disease.

Authors:  N J Davies; E A Shinebourne; M J Scallan; T A Sopwith; D M Denison
Journal:  Thorax       Date:  1984-12       Impact factor: 9.139

Review 7.  Pirbuterol. A preliminary review of its pharmacological properties and therapeutic efficacy in reversible bronchospastic disease.

Authors:  D M Richards; R N Brogden
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

8.  Effects of oral and inhaled salbutamol and oral pirbuterol on right and left ventricular function in chronic bronchitis.

Authors:  R J Winter; J A Langford; R M Rudd
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.